Compare ORIO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | 178 | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 26.0M |
| IPO Year | N/A | 2020 |
| Metric | ORIO | PASG |
|---|---|---|
| Price | $0.96 | $8.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.80 |
| AVG Volume (30 Days) | ★ 47.2K | 32.8K |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $78.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.28 |
| 52 Week High | $1.40 | $20.00 |
| Indicator | ORIO | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 49.93 |
| Support Level | N/A | $6.71 |
| Resistance Level | $1.27 | $8.94 |
| Average True Range (ATR) | 0.06 | 0.73 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 18.92 | 83.74 |
Orion Digital Corp is a digital finance company operating across wealth, payments, and digital assets. Through its Investing wealth platform, Carta World-wide payments infrastructure, and long-duration Bitcoin treasury plan - combined with a disciplined, multi-engine compounding model. Orion Digital is focused on compounding value through execution, scale, and capital discipline.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.